BDBM292057 3-(7-Chloro-1H-indazol-5-yl)-2-cyclobutyl-5-(trifluoromethyl)-2H-pyrazolo[4,3-::US10100045, Example 28
SMILES: FC(F)(F)c1ccc2nn(C3CCC3)c(-c3cc(Cl)c4[nH]ncc4c3)c2n1
InChI Key: InChIKey=WRAAGCYHBFTNQN-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Voltage-dependent calcium channel gamma-2 subunit (Homo sapiens (Human)) | BDBM292057 (3-(7-Chloro-1H-indazol-5-yl)-2-cyclobutyl-5-(trifl...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.0200 | n/a | n/a | n/a | n/a | 7.4 | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description Cell expressing the GRIA1o-CACNG8 fusion construct were grown in a monolayer in 96- or 384-well microtiter plates. They were washed with assay buffer... | US Patent US10100045 (2018) BindingDB Entry DOI: 10.7270/Q2MW2K56 | |||||||||||
More data for this Ligand-Target Pair |